AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Precipio Terminates Sales Agreement with A.G.P.
ByAinvest
Wednesday, Sep 3, 2025 5:49 pm ET1min read
Precipio Inc., a healthcare biotechnology company, has terminated its sales agreement with A.G.P. The company is focused on cancer diagnostics and develops diagnostic products, reagents, and services to improve accuracy and efficiency. Its technologies include HemeScreen and IV-Cell, which address diagnostic mistakes and improve testing processes. Precipio has laboratory and R&D facilities in Connecticut and Nebraska.
NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) — Precipio Inc., a healthcare biotechnology company specializing in cancer diagnostics, has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). This move underscores the company's commitment to responsible capital management and its growing financial stability.Precipio's CEO, Ilan Danieli, stated, "Our company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations and recent increases in our cash balance, we no longer need to rely on a tool like this for capital raises." This decision marks another step in the company's strategy to create shareholder value [1].
Precipio is dedicated to addressing the pervasive problem of cancer misdiagnoses by developing innovative diagnostic products and services. Their technologies, HemeScreen and IV-Cell, are designed to improve diagnostic accuracy and efficiency. HemeScreen tests for various mutations, while IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages, streamlining the testing process [2].
The company's laboratory and research and development (R&D) facilities are located in New Haven, Connecticut, and Omaha, Nebraska. Precipio's mission is to enhance diagnostic outcomes and reduce healthcare expenses by providing higher accuracy and improved laboratory workflows.
References:
[1] https://finance.yahoo.com/news/precipio-terminates-atm-140000076.html
[2] https://www.marketscreener.com/news/precipio-terminates-its-at-the-market-instrument-ce7c50d3d08af62d
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet